Thank you, John.
the the integral going would stakeholders of Before turning all keep the our the optic the thank clinical progress growing Phase of to our like ability been LOGICS development pandemic. I have to RECORLEV to specifics III who in studies program, related despite to and
been the our during research crisis the mitigate our and staff, employees, to have organizations contract working research study impact this partners vendor together Our efforts. development to health our global and and research participants
we to measures or make their have us that have While allowed many organizations in altogether, trial. other to been had LOGICS to fortunate delay innovative the clinical have continue programs progress stop
the sanctions health supply visits, transportation visits special protocol be instrumental telemedicine, monitoring study. as study complete to Specifically for such in helping and safely proving participants, drug direct-to-patient flexibility home are authority in with and clinical our measures the investigators and regulatory trial partnership arrangements, sites, required delivery
be we closing As LOGICS double-blind comprised Screening, enrollment or Please mentioned, before randomized phases. withdrawal to on May are the Phase of placebo-controlled XXth. a four is study randomized maintenance, titration John LOGICS withdrawal III study recall that in restoration. excited and
primary The the the phase. endpoint comes end randomized of withdrawal at
results will top-line end Our this the of data consist of through phase.
in XX versus approximately power allows observed hypothesis. endpoint have protocol loss that dependent due participants a scheduled one withdrawal XX% of other discontinuation targets rate completion. the As the to XX patient rate awaiting approximately May is date. is phase XX be LOGICS who that of study providing in detect There randomized today, determines of on of placebo range withdrawal, Recall logic the The will issues, of close the or in arm XXth the response primary logistical before towards the range to endpoint. targeted the null patient by XX% in on the to event primary for the of randomization in other This completers. has number enrollment currently able the to In primary additional or the patient arm progressing randomize the therapeutic sample completers and study which one levoketoconazole protocol enrollment. And participant for randomized size final XX% the imminently. endpoint is randomized that not completed
while have have phase withdrawal Therefore, randomized the achieve to in we up originally expected. at targeting to for approximately been much rates than XX enrollment lower least XX been subjects completers. Dropout to XX
XX As we already of and have today, subjects completers. have enrolled XX
titration maintenance in earlier, the mentioned patient have imminently. randomizing phase one we I As anticipate we who
end we XXth, discontinued we before neither such due many XXXX. company to As visit. continues and LOGICS the as quarter to the close impact subjects' XX unanticipated anticipate Barring patients during their the point when enrolled to a top-line on May XX the to Covid-XX results any expect completers if moment as third study up of prior from reaching have to primary or of reporting the pandemic,
As relates LOGICS can to continue and an NDA we six an months NDA submit approximately it receiving to them. after that believe reporting top-line results submission, we
expect PDUFA of for new substance our barring modifications of unanticipated Covid-XX due review date submission, NDA time FDA the review, to previously, we the review is can via cycle the we As if a pathway from pandemic. believe of stated active is any which cycle XXX(b)X that the standard accepted for a NDA XX-months
the closing, Endocrinology, congresses. of I European Congress Society commitments these In like had to Endocrinologist to would has accepted Strongbridge at the and their the American to meetings. annual thank for Association meeting finding solutions organizers exchanges three enable the for absent Endocrinology at their upcoming important scientific submissions virtual Clinical of
the Meeting. in-person in will issue and Design Study the lieu of supplemental Illogic May First an Methodology Journal be April, Annual published Endo of the American Society in of Poster
phase and will And of SONICS year. presentation date ECE III Phase Dr. results accepted the the an from published from learning be by the in for was of presentation additional Fleseriu system at as the finally, determined for management extended recorded oral on the in later virtual And Maria May. Abstracts in Endocrine by an presentation XXXX. publication evaluation phase evaluation AACE's extensive delivered Second SONICS study to results be
review And with from quarter that I Rob? up to the to financial Rob before open call first CFO who we questions. highlights Lutz, call over the will will turn the
